For Patients: VACO Index COVID-19 Mortality Risk
ورودیهای بالینی بیمار
حداقل ۲۰ — حداکثر ۱۱۵ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Lower Risk0–8.7
- Moderate Risk8.8–16
- High Risk16.1–21.2
- Extreme Risk21.3–100
The For Patients: VACO Index COVID-19 Mortality Risk calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates 30-day mortality risk after COVID-19 infection using pre-existing health conditions and demographics. Developed by researchers from Yale University and VA Connecticut Healthcare System in collaboration with the US Department of Health and Human Services.
Clinical Indication
The For Patients: VACO Index COVID-19 Mortality Risk is indicated for bedside clinical practice to support Estimates 30-day mortality risk after COVID-19 infection using pre-existing health conditions and demographics. Developed by researchers from Yale University and VA Connecticut Healthcare System in collaboration with the US Department of Health and Human Services.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
Uses age-specific coefficients, sex coefficients, and Charlson Comorbidity Index points with interaction terms. Final risk = exp(coefficient_sum) / (1 + exp(coefficient_sum))
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years(years) |
| sex | string | Yes | Patient biological sex |
| diabetes | string | Yes | Diabetes mellitus status and severity (0-2 points) |
| chronic_pulmonary_disease | string | Yes | Chronic pulmonary disease status (0-1 point) |
| renal_disease | string | Yes | Kidney/renal disease status and severity (0-2 points) |
| peripheral_vascular_disease | string | Yes | Peripheral vascular disease status (0-1 point) |
| congestive_heart_failure | string | Yes | Congestive heart failure status (0-1 point) |
| dementia | string | Yes | Dementia status (0-1 point) |
| cancer | string | Yes | Cancer status and severity (0-6 points) |
| cerebrovascular_accident | string | Yes | Stroke/cerebrovascular accident history (0-1 point) |
| liver_disease | string | Yes | Liver disease status and severity (0-3 points) |
| myocardial_infarction | string | Yes | Myocardial infarction (heart attack) history (0-1 point) |
| peptic_ulcer_disease | string | Yes | Peptic ulcer disease history (0-1 point) |
| paralysis | string | Yes | Paralysis status (0-1 point) |
| aids | string | Yes | AIDS/HIV status (0-6 points) |
| rheumatologic_disease | string | Yes | Rheumatologic disease status (0-1 point) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–8.7 | Lower Risk | Lower risk of 30-day mortality |
| 8.8–16 | Moderate Risk | Moderate risk of 30-day mortality |
| 16.1–21.2 | High Risk | High risk of 30-day mortality |
| 21.3–100 | Extreme Risk | Extreme risk of 30-day mortality |
Evidence-Based References (EBM)
- Justice AC, Freiburg MS, Lopez-Class M, et al. Patient-facing COVID-19 risk tool. Developed in collaboration with US Department of Health and Human Services. Yale University and VA Connecticut Healthcare System; 2020.
- King JT Jr, Yoon JS, Rentsch CT, et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLoS One. 2020;15(11):e0241825.
- Rentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study. PLoS Med. 2020;17(9):e1003379.